Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.

Last updated: December 9, 2024
Sponsor: First Affiliated Hospital of Ningbo University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bronchiectasis

Treatment

Bronchoalveolar Lavage

Clinical Study ID

NCT06726356
2024-R036-01
  • Ages 18-80
  • All Genders

Study Summary

Bronchiectasis is a clinical syndrome characterised by chronic cough, profuse sputum and/or intermittent haemoptysis, with or without shortness of breath and respiratory failure of varying severity, and abnormal thickening and dilatation of the bronchial walls as seen on lung imaging. Nebulised inhalation of N-acetylcysteine has been shown to significantly improve symptoms, shorten the length of hospital stay, reduce the rate of re-hospitalisation within six months, and improve lung function in patients with bronchiectasis with a high degree of safety. There have been no studies on the efficacy and safety of bronchoscopic irrigation with N-acetylcysteine solution in the treatment of bronchiectasis. The aim of this study was to investigate whether bronchoscopic acetylcysteine lavage combined with conventional treatment is more beneficial to patients with bronchiectasis than conventional treatment combined with conventional bronchoalveolar lavage and conventional treatment without bronchoscopy, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years and ≤80 years;

  2. Chest CT suggestive of bronchiectasis;

  3. meet the criteria for an acute exacerbation of bronchiectasis with symptoms such ascough, sputum, chest tightness or wheezing, and c. Patients who meet the criteriafor an acute exacerbation of bronchiectasis with symptoms of cough, sputum, chesttightness or wheezing and who consent to bronchoscopy with bronchoalveolar lavage

  4. patients who agreed to participate in the study and signed an informed consent form;

Exclusion

Exclusion Criteria:

  1. Severe cardiopulmonary diseases, coagulation disorders, poor tolerance toanaesthesia, psychiatric disorders or severe neuroses that are contraindications tobronchoscopy;

  2. Intraoperative findings of decreased SPO2 or inability to tolerate bronchoscopy orinability to tolerate further bronchoalveolar lavage;

  3. Inability to co-operate with the study for any reason or in the opinion of theinvestigator, inappropriate for inclusion in the study for other reasons;

  4. Bronchoscopy of patients with significant intra-airway haemorrhage who may be atrisk of exacerbation due to bronchoalveolar lavage;

  5. Patients with acetylcysteine allergy;

  6. Missing information;

Study Design

Total Participants: 180
Treatment Group(s): 1
Primary Treatment: Bronchoalveolar Lavage
Phase:
Study Start date:
August 14, 2024
Estimated Completion Date:
July 30, 2026

Study Description

All patients enrolled were patients with acute exacerbation of bronchiectasis. A total of 180 patients (1:1:1 allocation) with acute exacerbation of bronchiectasis were to be enrolled. The patients were divided into control group A (conventional clinical treatment including anti-infective and expectorant therapy), control group B (bronchoalveolar lavage with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml), and experimental group C (bronchoalveolar lavage with acetylcysteine solution in combination with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml).

Connect with a study center

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang 315010
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.